Loading...

OVID OVID THERAPEUTICS INC Company Mergers 8-K Filing

VD T

VD

OVID THERAPEUTICS INC

(OVID)

2025 8-K

Show Summary

Show Summary

Asset Acquisitions

Financial Results

Board Appointment

Q3 2024 Results

Management Change

Q2 2024 Results

Departure of Directors

Annual Meeting Results

Earnings Reports

Financial Results

Earnings Reports

Earnings Reports

Annual Meeting Results

Earnings Reports

Collaboration and License A...

Financial Results Announcement

Regulation FD Disclosure

External Links:

On June 25, 2025, Ovid Therapeutics Inc. announced it entered a licensing agreement amendment with Immedica Pharma, allowing an upfront payment of $7 million in exchange for royalty obligations related to its patent for ganaxolone.

AI Assistant

OVID THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.